HENLIUS (Stock Code: 02696) Announces IND Approval for KAT6A/B Inhibitor HLX97 in Advanced/Metastatic Solid Tumors

Bulletin Express03-05

Shanghai Henlius Biotech, Inc. announced that its investigational new drug application for HLX97 (a KAT6A/B small molecule inhibitor) has been approved by the National Medical Products Administration to commence a Phase 1 clinical trial in patients with advanced or metastatic solid tumors. According to the announcement, HLX97 was developed to inhibit the activity of the lysine acetyltransferases KAT6A/B, which are considered significant in the progression of certain tumor types. Breast cancer studies suggest that suppressing KAT6 may help overcome resistance to endocrine therapy.

The announcement observes that there is no existing global approval for a KAT6A/B small molecule inhibitor, highlighting the potential significance of this therapy. The company states it cannot guarantee successful development or commercialization, and advises shareholders and potential investors to exercise caution when dealing in its shares.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1143997039?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-05 17:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1143997039","market":"us","top_or_hot":-1,"title":"HENLIUS (Stock Code: 02696) Announces IND Approval for KAT6A/B Inhibitor HLX97 in Advanced/Metastatic Solid Tumors","media":"Bulletin Express","content":"<p>Shanghai Henlius Biotech, Inc. announced that its investigational new drug application for HLX97 (a KAT6A/B small molecule inhibitor) has been approved by the National Medical Products Administration to commence a Phase 1 clinical trial in patients with advanced or metastatic solid tumors. According to the announcement, HLX97 was developed to inhibit the activity of the lysine acetyltransferases KAT6A/B, which are considered significant in the progression of certain tumor types. Breast cancer studies suggest that suppressing KAT6 may help overcome resistance to endocrine therapy.</p>\n<p>The announcement observes that there is no existing global approval for a KAT6A/B small molecule inhibitor, highlighting the potential significance of this therapy. The company states it cannot guarantee successful development or commercialization, and advises shareholders and potential investors to exercise caution when dealing in its shares.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HENLIUS (Stock Code: 02696) Announces IND Approval for KAT6A/B Inhibitor HLX97 in Advanced/Metastatic Solid Tumors</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHENLIUS (Stock Code: 02696) Announces IND Approval for KAT6A/B Inhibitor HLX97 in Advanced/Metastatic Solid Tumors\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-03-05 17:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shanghai Henlius Biotech, Inc. announced that its investigational new drug application for HLX97 (a KAT6A/B small molecule inhibitor) has been approved by the National Medical Products Administration to commence a Phase 1 clinical trial in patients with advanced or metastatic solid tumors. According to the announcement, HLX97 was developed to inhibit the activity of the lysine acetyltransferases KAT6A/B, which are considered significant in the progression of certain tumor types. Breast cancer studies suggest that suppressing KAT6 may help overcome resistance to endocrine therapy.</p>\n<p>The announcement observes that there is no existing global approval for a KAT6A/B small molecule inhibitor, highlighting the potential significance of this therapy. The company states it cannot guarantee successful development or commercialization, and advises shareholders and potential investors to exercise caution when dealing in its shares.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02696","symbol_name":"复宏汉霖","start_time":0,"source_url":"","article_id":"1143997039","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1143997039","pubTimestamp":1772703182,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Shanghai Henlius Biotech, Inc. announced that its investigational new drug application for HLX97 (a KAT6A/B small molecule inhibitor) has been approved by the National Medical Products Administration...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02696":"复宏汉霖"},"translate_title":"复宏汉霖（股票代码：02696）宣布KAT6A/B抑制剂HLX97用于晚期/转移性实体瘤的IND获批","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02696":1},"content_text":"Shanghai Henlius Biotech, Inc. announced that its investigational new drug application for HLX97 (a KAT6A/B small molecule inhibitor) has been approved by the National Medical Products Administration to commence a Phase 1 clinical trial in patients with advanced or metastatic solid tumors. According to the announcement, HLX97 was developed to inhibit the activity of the lysine acetyltransferases KAT6A/B, which are considered significant in the progression of certain tumor types. Breast cancer studies suggest that suppressing KAT6 may help overcome resistance to endocrine therapy.\nThe announcement observes that there is no existing global approval for a KAT6A/B small molecule inhibitor, highlighting the potential significance of this therapy. The company states it cannot guarantee successful development or commercialization, and advises shareholders and potential investors to exercise caution when dealing in its shares.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1143997039","isCrawlerRequest":true}